Bruce Bracken, MD - 4/26/23



  • Born in Winnipeg Manitoba
  • Obtained M.D. from UNiversity of Manitoba
  • Urology Training University of Michigan
  • Fellowship Training- Memorial Sloan Kettering Cancer Center, New York City
  • 7 years as a urologist at M.D. Anderson Cancer Center, Houston Texas
  • 41 years as a urologist at The University of Cincinnati
  • Retiring from UC on 12/31/2022
  • Part Time Urologist Dayton Veterans Administration Hospital


  • About 140 publications
  • 1 book
  • About 70 Principal Investigator of Prospective Randomized Controlled Trials


Bachelor's Degree: University of Manitoba 1962

Medical Degree: University of Manitoba 1966

General Surgery Residency: Winnipeg General Hospital 1970

Urology Residency: University of Michigan 1973

Fellowship in Urologic Oncology : Memorial Hospital for Cancer and Allied Diseases 1974


American Board of Urology (Certification Date: 02-28-1975 )

Clinical Interests


Lower Urinary Tract Symptoms

Male Genitalia Cancers

Male Urogenital Diseases

Maple Syrup Urine Disease



Penile Cancer

Prostate Cancer

Prostatic Hyperplasia

Prostatic Intraepithelial Neoplasia


Retractile testicle

Scrotal masses


Sertoli Cell Tumor

Sertoli-Leydig Cell Tumor


Spermatic Cyst



Testicular Cancer

Testicular Hydrocele

Testicular Torsion

Undescended Testicle (Cryptorchidism)

Ureteral Cancer

Ureteral Disease

Urethral Cancer

Urinary Bladder Disease

Urination Disorders

Urine Retention

Urogenital Cancers

Urogenital System

Urologic Cancer

Urologic Disease

Research and Practice Interests

Urologic Oncology

Research Support

Grant: #5-R01-CA-58989-03-A0-S0-E0 Investigators:Bracken, R. Bruce 04-01-2001 -05-31-2002 National Cancer Institute Pharm Based Efficacy Trial of Intravesical Mitomycin C Role:PI $4,200.00 Closed Level:Federal

Grant: #PCPT9307 CA37429 Investigators:Bracken, R. Bruce 11-28-2001 -05-31-2013 National Cancer Institute Selenium and Vitamin E Chemoprevention Trial Role:PI $46,664.50 Closed Level:Federal

Grant: #4-U10-CA-37429-18-A0-S0-E1 Investigators:Bracken, R. Bruce 06-01-1993 -05-31-2003 National Cancer Institute SWOG Prostate Cancer Prevention Role:PI $243,639.03 Closed Level:Federal

Grant: #CA37429-SWOG-SELECT-10 Investigators:Bracken, R. Bruce 04-21-2010 -05-31-2013 National Cancer Institute SWOG - Selenium and Vitamin E Cancer Prevention Trial (SELECT) Role:PI $6,500.00 Closed Level:Federal

Grant: #K07 CA138714 Investigators:Bracken, R. Bruce; Ho, Shuk Mei; Lemasters, Grace; Rao, Marepalli; Succop, Paul; Wu, Tianying 09-08-2010 -08-31-2015 National Cancer Institute Global and Specific Oxidation Pathways Related to Prostate Cancer, Prospective and Cross-Sectional Analyses Role:Collaborator $656,117.00 Active Level:Federal


Peer Reviewed Publications

Oleksowicz, Leslie; Liu, Yin; Bracken, R Bruce; Gaitonde, Krishnanath; Burke, Barbara; Succop, Paul; Levin, Linda; Dong, Zhongyun; Lu, Shan (2012. ) Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.The Prostate, , 72 (10 ) ,1140-9More Information

Dong, Zhongyun; Liu, Yin; Scott, Kieran F; Levin, Linda; Gaitonde, Krishnanath; Bracken, R Bruce; Burke, Barbara; Zhai, Qihui Jim; Wang, Jiang; Oleksowicz, Leslie; Lu, Shan (2010. ) Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.Carcinogenesis, , 31 (11 ) ,1948-55More Information

Tripp, Lloyd D; Warm, Joel S; Matthews, Gerald; Chiu, Peter Y; Bracken, R Bruce (2009. ) On tracking the course of cerebral oxygen saturation and pilot performance during gravity-induced loss of consciousness. Human factors, , 51 (6 ) ,775-84

Sweets, Thomas; Bracken, R Bruce; Geisler, Eric J; Warnick, Ronald (2009. ) Intracranial treatment for solitary prostatic adenocarcinoma brain metastasis is curative.Urology, , 73 (3 ) ,681.e7-9More Information

Bruskewitz, R; Girman, C J; Fowler, J; Rigby, O F; Sullivan, M; Bracken, R B; Fusilier, H A; Kozlowski, D; Kantor, S D; Johnson, E L; Wang, D Z; Waldstreicher, J (1999. ) Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology, , 54 (4 ) ,670-8

Roehrborn, C G; Boyle, P; Bergner, D; Gray, T; Gittelman, M; Shown, T; Melman, A; Bracken, R B; deVere White, R; Taylor, A; Wang, D; Waldstreicher, J (1999. ) Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology, , 54 (4 ) ,662-9

Schellhammer, P F; Mardovin, W; Davis, N S; Bracken, R B; Stephenson, R A (1997. ) Summary of transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer (by Paul F. Schellhammer, MD, and Willet F. Whitmore, Jr, MD). 1976. Seminars in urologic oncology, , 15 (2 ) ,99-104

Hedden, R J; Husseinzadeh, N; Bracken, R B (1993. ) Bladder sparing surgery for locally advanced female urethral cancer. The Journal of urology, , 150 (4 ) ,1135-7

Tricoli, J V; Yao, J L; D'Souza, S A; Bracken, R B (1993. ) Detection of sex-region Y (SRY) transcripts in human prostate adenocarcinoma and benign prostatic hypertrophy. Genes, chromosomes & cancer, , 8 (1 ) ,28-33

Tricoli, J V; Bracken, R B (1993. ) ZFY gene expression and retention in human prostate adenocarcinoma. Genes, chromosomes & cancer, , 6 (2 ) ,65-72

Dodd, G D; Kaufman, P N; Bracken, R B (1991. ) Renal arterial duplex Doppler ultrasound in dogs with urinary obstruction. The Journal of urology, , 145 (3 ) ,644-6

Douglas, C; Burke, B; Kessler, D L; Cicmanec, J F; Bracken, R B (1990. ) Microwave: practical cost-effective method for sterilizing urinary catheters in the home. Urology, , 35 (3 ) ,219-22

Schwartz, B R; Gregg, R V; Kessler, D L; Bracken, R B (1989. ) Continuous postoperative epidural analgesia in management of postoperative surgical pain. Urology, , 34 (6 ) ,349-52

Stoner E.;Bracken R.;Stein E.;Franke K.;Geller J.;Pratt C.;Imperato- McGinley J.;Vaughan E.;Orlic S.;McConnell J.;Wilson J.;Hill L.;Roy J.;Einfeldt S.;Tenover L.;Zeitner M.;Pappas F.;Gregg H. (01-01-1992. ) The clinical effects of a 5?-reductase inhibitor, finasteride, on benign prostatic hyperplasia.Journal of Urology, , 147 (5 ) ,1298-1302More Information

Lian C.;Bracken R. (06-01-1991. ) Urinary catheter sterilization with microwave oven.International Urogynecology Journal, , 2 (2 ) ,94-97More Information

Shank R.A.;Barnes M.M.;Benz S.A.;Bracken R.B. (01-01-1990. ) Innovation in urodynamic testing: Report of the first fully computerized work station.Neurourology and Urodynamics, , 9 (2 ) ,155-164More Information

Bracken R.;Johnson D.;Frazier O.;Logothetis C.;Trindade A.;Samuels M. (01-01-1983. ) The role of surgery following chemotherapy in stage III germ cell naoplasms.Journal of Urology, , 129 (1 ) ,39-43More Information

Guarda L.;Jaffe N.;Bracken R.;Ayala A. (01-01-1982. ) Chemotherapeutic-induced histologic changes in Wilms' tumors .Laboratory Investigation, , 46 (1 ) ,

Samuels M.;Johnson D.;Bracken R. (01-01-1979. ) Adjuvant chemotherapy in testis cancer.International Journal of Radiation Oncology Biology Physics, , 5 (SUPPL. 1 ) ,48More Information

Bracken R.;Johnson D.;Miller L.;Ayala A.;Gomez J.;Rutledge F. (01-01-1977. ) Primary carcinoma of the female urethra.Obstetrical and Gynecological Survey, , 32 (2 ) ,118-119More Information

Zornoza J.;Bracken R.;Wallace S. (01-01-1976. ) Radiologic features of adrenal metastases.Urology, , 8 (3 ) ,295-299More Information

Bracken R.;Johnson D.;Miller L.;Ayala A.;Gomez J.;Rutledge F. (01-01-1976. ) Primary carcinoma of the female urethra.Journal of Urology, , 116 (2 ) ,188-192More Information

Goldstein H.;Medellin H.;Beydoun M.;Wallace S.;Ben-Menachem Y.;Bracken R.;Johnson D. (01-01-1975. ) Transcatheter embolization of renal cell carcinoma.AMER.J.ROENTGENOL., , 123 (3 ) ,557-562More Information

Other Information

Division of Urology,

Contact Information

Dr. Sidana

Academic - Medical Sciences Building
Room 2519
Cincinnati  Ohio, 45267
Phone: 513-558-4388